Author's Response to comments on: "Comparison of postoperative cyclosporine 2.0% versus betamethasone 0.1% eye drops following trabeculectomy: A randomized clinical trial". [PDF]
Indian J OphthalmolDaneshvar R.
europepmc +1 more source
Recent improvement in clinical pancreas transplantation [PDF]
, 1987 Abendroth, D. +4 more
core +1 more source
Cell Proliferation, EarlyView.Clinical‐grade HLA‐homozygous iPSC‐derived neural precursor cells restore motor function, rebuild striatal circuitry and reduce neuroinflammation in QA‐lesioned rats. These findings demonstrate robust neuronal replacement and microenvironment modulation, supporting their potential as a regenerative therapy for Huntington's disease.
Hyeonjoong Jeon +6 more
wiley +1 more source
Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases: A Single-Center Cross-Sectional Study From a Tertiary Care Center in Bangladesh. [PDF]
CureusAhmed K +5 more
europepmc +1 more source
Cyclosporine and its metabolites in mother and baby [PDF]
, 1988 Burckart, GJ +5 more
core +1 more source
Drug‐induced hypersensitivity syndrome followed by exacerbation of Crohn's disease
Pediatric Investigation, EarlyView.
Mei Kamidani +10 more
wiley +1 more source
Wells syndrome: clinical findings and management in a large cohort of 48 patients
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and Objectives: Wells syndrome (WS) is a rare inflammatory skin disorder typically characterized by erythematous, edematous, and pruritic plaques. Despite its distinct histopathological features, WS remains an underdiagnosed disease due to its variable clinical presentations and overlap with other dermatological conditions.
Marco Adriano Chessa +8 more
wiley +1 more source
Comment on: Comparison of postoperative cyclosporine 2.0% versus betamethasone 0.1% eye drops following trabeculectomy: A randomized clinical trial. [PDF]
Indian J OphthalmolVaradhan N, Srikanth K.
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley +1 more source